Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Lenvatinib, and SBRT for HCC with PVTT
NCT05286320Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Mar 2023
- Primary completion
- Sep 2026
- Countries
- 1
- Sponsor
- National Taiwan University Hospital
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Primary endpoints: Safety rate and Objective Response Rate at 2.5 years. Planned start Mar 2023; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Lenvatinib/Pembrolizumab plus SBRT
Pembrolizumab + Lenvatinib + SBRT
03
Endpoints
Primary
Safety rate
Objective Response Rate
Secondary
Progression-Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT05286320.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286320.